Rapid advancements in the area of early cancer detection have brought us closer to
achieving the goals of finding cancer early enough to treat or cure it, while avoiding harms of …

Liquid biopsies that detect circulating tumour DNA (ctDNA) have the potential to
revolutionise the personalised management of colorectal cancer. For patients with early …

Gastroesophageal cancer dynamics and drivers of clinical responses with immune
checkpoint inhibitors (ICI) remain poorly understood. Potential synergistic activity of dual …

Circulating cell-free DNA (cfDNA) assays for monitoring individuals with cancer typically rely
on prior identification of tumor-specific mutations. Here, we develop a tumor-independent …

Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to
immunotherapy. BR. 36 is a multi-center, randomized, ctDNA-directed, phase 2 trial of …

Introduction: The standard treatment for locally advanced rectal cancer (LARC) is
neoadjuvant chemoradiotherapy (nCRT). To select patients who would benefit the most from …

Ovarian cancer is a leading cause of death for women worldwide, in part due to ineffective
screening methods. In this study, we used whole-genome cell-free DNA (cfDNA) …

Introduction Most patients with pancreatic cancer present with advanced stage, incurable
disease. However, patients with high-grade precancerous lesions and many patients with …

Background There is accumulating evidence supporting the clinical use of circulating tumor
DNA (ctDNA) in solid tumors, especially in different types of gastrointestinal cancer. As such …

Colorectal cancer is a common malignant tumor of the digestive tract. Despite advances in
diagnostic techniques and medications. Its prognosis remains challenging. DNA methylation …